Light therapy market seen reaching $1.74 billion by 2035

Market Research Future projects the global light therapy market will grow from $1.15 billion in 2026 to $1.74 billion by 2035, driven by lower LED costs, home-use phototherapy adoption and new regulatory clearances. The strongest demand is coming from dermatology, mental health and ophthalmology, while home care and consumer devices are gaining ground.

Why it matters: - Lower-cost LED components and broader home-use validation are pushing light therapy from clinic-only treatment toward consumer and decentralized care. - New clearances in ophthalmology and expanding use in mental health and skin care are opening revenue streams beyond traditional dermatology. - The market's projected growth to $1.74 billion by 2035 points to steady demand across medical and consumer channels.

What happened: - Market Research Future projects the global light therapy market will rise from $1.15 billion in 2026 to $1.74 billion by 2035. - The forecast implies a 4.72% compound annual growth rate from 2026 to 2035. - The market base was estimated at $1.10 billion in 2025. - The report cites a free sample and a customization request page: Request a free sample and Ask for customization.

The details: - Gallium nitride LED wafer prices fell about 18% from 2021 to 2025. - Therapeutic-grade devices are now available at consumer price points below $200. - Modern LED panels deliver 40% more irradiance per watt than 2019 models. - The FDA's 2024 authorization of LumiThera's Valeda Light Delivery System for dry age-related macular degeneration created a new ophthalmic use case. - The report estimates that clearance could support an annual revenue stream worth about $120 million by 2030. - The European Medicines Agency has fast-tracked review pathways for three LED-based wound care devices since 2023. - The chronic wound care addressable market tied to those devices exceeds $8 billion globally. - Global depression diagnoses increased 28% between 2019 and 2024, according to WHO data. - Seasonal affective disorder affects an estimated 10 million Americans a year. - Nordic countries have integrated structured light therapy into national mental health guidelines. - Canadian provincial health plans expanded phototherapy coverage for major depressive disorder with seasonal pattern in 2024. - Light boxes were the largest product category in 2025, with about 29.1% revenue share. - Hand-held devices were the fastest-growing product category, at a 5.20% CAGR from 2026 to 2035. - Blue light held about 37.9% of revenue in 2025 and remained the dominant light type. - Red light was the fastest-growing light type segment, at a 5.08% CAGR from 2026 to 2035. - Skin disorders led applications in 2025 with about 31.8% revenue share. - Depression and sleep-cycle disorders were the fastest-growing application segment, at 5.30% CAGR from 2026 to 2035. - Dermatology clinics were the largest end-user group in 2025, with about 43.2% revenue share. - Home-care settings were the fastest-growing end-user segment, at 5.34% CAGR from 2026 to 2035. - North America led the market in 2025 with about 47.4% share. - The United States generated about 78.5% of North American light therapy revenue. - Europe held about 26.0% of the market in 2025. - Asia-Pacific was the fastest-growing region, at a 5.39% CAGR from 2026 to 2035. - The Middle East and Africa accounted for about 4.1% of the market in 2025. - South America represented about $0.05 billion in 2025. - Koninklijke Philips N.V. held about 8% to 11% of global revenue in 2024-2025. - Verilux Inc. held about 5% to 8% of global revenue in 2024-2025. - Beurer GmbH expanded its TL line in January 2024 with a portable, USB-C rechargeable daylight therapy lamp priced at EUR 89. - BioLight Life Sciences held about 3% to 6% of global revenue in 2024-2025. - The market's top five companies held an estimated 38% to 44% combined revenue share. - More than 340 light therapy-related patent applications were filed in 2024. - Several startups have raised a combined $85 million in Series A and B funding since 2023 to develop closed-loop phototherapy systems. - The report expects AI-integrated closed-loop phototherapy systems to become a major operating model by 2030. - The report also expects 30% to 35% of clinic-delivered sessions could shift to home settings by 2032. - Market Research Future says home-use phototherapy devices with cellular connectivity and compliance tracking fit hospital-at-home expansion.

Between the lines: - The market is shifting from a specialist clinic model to a mixed model that includes home care, direct-to-consumer devices and digitally connected treatment. - Price declines in LEDs are lowering the barrier for consumer brands and expanding access beyond hospitals and dermatology offices. - Regulatory clearance in ophthalmology suggests light therapy is moving into more medically specific indications, not just wellness use. - The competitive field remains fragmented enough for both large medtech companies and niche consumer brands to compete.

What's next: - AI-enabled phototherapy systems are expected to gain traction as sensors and adaptive controllers improve treatment precision. - Home-use adoption should accelerate if reimbursement continues to expand for phototherapy devices. - Asia-Pacific is positioned to remain the fastest-growing region as local manufacturing lowers device costs. - More indication-specific clearances could widen the market beyond acne, seasonal affective disorder and general dermatology.

The bottom line: - Light therapy is moving into a broader, more distributed care market, with growth now tied to cheaper hardware, regulatory progress and rising demand for at-home treatment.